Protagonist Therapeutics, Inc. — Form 10-Q Summary
Business context and reporting period
Protagonist Therapeutics is a clinical-stage biopharmaceutical company developing peptide-based therapies for unmet medical needs. Its lead programs are PTG-100 for inflammatory bowel disease, PTG-200 for Crohn’s disease, and PTG-300 for iron-overload disorders. The filing covers the quarter and six months ended June 30, 2016; the financial statements are unaudited.
- PTG-100 completed a Phase 1 trial in healthy volunteers, with management planning to begin a Phase 2b ulcerative-colitis trial by the end of the fourth quarter of 2016.
- PTG-200 was in IND-enabling studies, with a Phase 1 trial planned for 2017.
- PTG-300 remained in preclinical development.
- The company had no approved products and no product revenue.
Financial metrics
| Metric | Three months ended June 30, 2016 | Three months ended June 30, 2015 | Six months ended June 30, 2016 | Six months ended June 30, 2015 |
|---|---|---|---|---|
| Research and development expense | $5.7 million | $2.3 million | $11.3 million | $4.5 million |
| General and administrative expense | $1.4 million | $0.8 million | $2.8 million | $1.3 million |
| Total operating expenses | $7.1 million | $3.1 million | $14.1 million | $5.8 million |
| Net loss | $7.1 million | $3.2 million | $18.8 million | $5.9 million |
| Net loss attributable to common stockholders | $7.3 million | $3.2 million | $19.1 million | $5.9 million |
| Basic and diluted loss per share | $19.07 | $13.78 | $56.90 | $25.55 |
| Net cash used in operating activities | Not presented for the quarter | Not presented for the quarter | $13.3 million | $5.9 million |
There was no revenue, gross profit, or operating margin because the company had not generated product sales. As of June 30, 2016, cash and cash equivalents were $13.8 million, available-for-sale securities were $6.4 million, and total cash, cash equivalents, and available-for-sale securities were approximately $20.2 million. The company reported no outstanding debt or credit facility and had an accumulated deficit of $46.3 million.
Total assets were $24.5 million, compared with $14.8 million at December 31, 2015. Current liabilities were $4.1 million, and stockholders’ deficit was $46.2 million. Redeemable convertible preferred stock had a carrying value of $66.6 million at June 30, 2016.
Material changes versus the prior comparable period
- Quarterly research and development expense increased 148% to $5.7 million, primarily because of PTG-100 clinical-trial costs, contract manufacturing, preclinical activities, increased headcount, consultants, and facilities.
- Six-month research and development expense increased 153% to $11.3 million. PTG-100 clinical development and manufacturing were the principal drivers.
- Quarterly general and administrative expense increased 77% to $1.4 million; six-month expense increased 117% to $2.8 million, mainly due to professional services and personnel costs.
- Six-month net loss increased $12.9 million, or 219%, to $18.8 million. The increase included a $4.2 million fair-value charge for the preferred-stock tranche liability and a $0.5 million charge for the preferred-stock warrant liability.
- In March 2016, the company completed the second tranche of its Series C preferred-stock financing, receiving $22.5 million net. The related tranche liability was settled and reclassified to preferred stock.
- In April 2016, warrants were exercised for approximately 2.0 million Series B preferred shares for $20,000; the remaining warrants expired unexercised in May 2016.
- Operating cash burn increased to $13.3 million from $5.9 million in the first six months of 2015, while financing cash inflow increased to $21.9 million from $57,000.
Guidance, outlook, risks, contingencies, and unusual items
Management stated that cash, cash equivalents, available-for-sale securities, and the subsequent IPO proceeds were expected to fund operations for at least 18 months based on the then-current plan. The company also stated that additional financing would be required to advance candidates through clinical development and that existing resources would not fund pivotal trials. The filing provides no revenue or profitability guidance.
- In August 2016, after the reporting date, the company completed an IPO of 7.5 million shares at $12.00 per share and received $83.7 million net of underwriting discounts and commissions, before offering costs. In September 2016, it received an additional $2.8 million net from the underwriters’ option exercise.
- The IPO converted all outstanding preferred stock into 8,577,571 common shares. A 1-for-14.5 reverse stock split was effected in August 2016, and historical share and per-share data were retrospectively adjusted.
- The company expects research and development spending to increase as PTG-100, PTG-200, PTG-300, and other programs advance.
- Key risks include clinical-trial failure or delay, regulatory nonapproval, patient-enrollment challenges, reliance on contract research organizations and manufacturers, product-supply disruptions, intellectual-property disputes, competition, uncertain reimbursement, and the need for additional capital.
- The company identified material weaknesses in internal control over financial reporting related to complex equity transactions and review and approval of manual journal entries. Disclosure controls and procedures were deemed ineffective at the end of the period. Remediation was in its early phases.
- The company had no material legal proceedings and no off-balance-sheet arrangements. It had approximately $128.5 million of potential development, regulatory, and sales milestones and low-single-digit royalties payable under the PTG-300 license arrangement if specified events occur.
Important facts for investors to verify
- Confirm the post-quarter IPO, option exercise, reverse split, and preferred-stock conversion effects on fully diluted share count and ownership.
- Assess whether the IPO proceeds and cash balance support the planned PTG-100 Phase 2b trial and PTG-200 and PTG-300 development timelines.
- Monitor PTG-100 Phase 2b initiation, trial enrollment, clinical results, and regulatory interactions.
- Track quarterly operating cash burn and the timing and amount of future financing needs.
- Evaluate progress in remediating the disclosed material weaknesses in internal controls.
- Review preferred-stock conversion terms, option dilution, potential license milestones and royalties, and the company’s dependence on third-party manufacturers and CROs.